D824V

One Perspective on the BLU-285 Trial (avapritinib/Ayvakit)

LRG members Jennifer & Owen Moore give their perspective on participating in the Phase I BLU-285 trial at OSHU with Dr. Michael Heinrich. After three other drug treatment lines and faced with several growing tumors, the BLU-285 (avapritinib) trial was Owen’s best option.

By |2020-03-09T10:18:42-04:00February 28th, 2020|D842V, News, Newsletter|

It’s a Journey: Our Experience on Clinical Trials

By Jennifer Moore, LRG Member I was waiting in line to pick up a new prescription for Gleevec when my husband ran in and told me to forget it. After two surgeries, a year [...]

By |2020-01-31T10:44:52-05:00December 28th, 2017|Clinical Trials, Member Stories, News, Newsletter|
Go to Top